FDA clears Biotronik's pacemaker with home monitor:
This article was originally published in Clinica
The US FDA has approved for sale Biotronik's Philos DR-T pacemaker with home monitoring technology, which is designed to automatically transmit critical data about the patient's current condition to the physician's office. The home monitor system will be incorporated in future product lines, including implantable cardioverter defibrillators, said the Lake Oswego, Oregon firm.
You may also be interested in...
A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.